Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer. (September 2019)

• Record Type: Journal Article
• Authors: Shivji, Alisha; Ali, Raafi; North, Scott; Sawyer, Michael; Ghosh, Sunita; Chambers, Carole
• Is Part Of: Journal of oncology pharmacy practice. Volume 25:Number 6(2019)
• Page Start: 1293
• Page End: 1300
• Publication Date: 2019-09
• Subjects: Real world evidence -- abiraterone -- prostate cancer -- docetaxel; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155218784716
• Languages: English
• ISSNs: 1078-1552

Abstract

Objectives: The COU-AA-301 trial demonstrated that in men with metastatic castrate-resistant prostate cancer using abiraterone post-docetaxel increased overall survival. This study aims to assess this conclusion in a real world context. Design: Retrospective chart review of a provincial Pharmacy BDM Database (a pharmacy dispensing software) and a provincial Electronic Chart (ARIA). Dispensing data, information on the state of the disease before and after abiraterone use, and information regarding effects of abiraterone were gathered. Setting: Cancer centers in Alberta, Canada. Patients: Metastatic castrate-resistant prostate cancer (CRPC) patients on abiraterone outside of a clinical trial who have previously had docetaxel chemotherapy for CRPC between February 2012 and May 2014. Primary outcome: Overall survival from the time of abiraterone initiation. Results: Overall survival increase of 17 months was consistent with the survival increase of 14.8 months observed in the pivotal trial. Conclusion: Abiraterone is a valuable therapy post-docetaxel for metastatic CRPC, as in a real world context it demonstrated an increase in overall survival that was consistent with the findings of the clinical trial despite including a patient population of older age and lower performance status.